21 Important Drug Approvals You Need to Know

OMEGAVEN (fish oil triglycerides, Fresenius Kabi) Indications: A source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). LUMOXITI (moxetumomab pasudotox-tdfk, AstraZeneca) Indications: Treatment of adult patients with relapsed or refractory h...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2018-11, Vol.162 (11), p.39-41
Main Author: Hamm, Nicholas
Format: Article
Language:English
Subjects:
Adults
Contraindications
Drug dosages
FDA approval
Gottlieb, Scott
Infections
Leukemia
Lymphoma
Metastasis
Migraine
Mutation
Pediatrics
Pharmaceuticals
Pharmacists
Triglycerides
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OMEGAVEN (fish oil triglycerides, Fresenius Kabi) Indications: A source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). LUMOXITI (moxetumomab pasudotox-tdfk, AstraZeneca) Indications: Treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog Dosage: 0.04 mg/kg as an intravenous infusion over 30 minutes on days 1, 3, and 5 of each 28-day cycle. VIZIMPRO (dacomitinib, Pfizer) Indications: First-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
ISSN:0012-6616
1937-8157